4593.T Live signaler | Maksimer profitt med Getagraph.com

Live Chart Being Loaded With Signals

Commentary (1 mai 2024 @ 08:15):

Healios K.K. engages in the research and development, manufacture, and sale of cell therapy and regenerative medicine products in Japan, Europe, and the United States...

Stats
Dagens volum	213 800
Gjennomsnittsvolum	1.40M
Markedsverdi	13.34B
EPS	¥0 ( 2024-02-13 )
Neste inntjeningsdato	( ¥-4.96 ) 2024-05-09
Last Dividend	¥0 ( N/A )
Next Dividend	¥0 ( N/A )
P/E	-2.63
ATR14	¥0.204 (0.14%)

Volum Korrelasjon

Lang: -0.06 (neutral)

Kort: 0.00 (neutral)

Signal:(52.781) Neutral

Healios K.K. Korrelasjon

10 Mest positive korrelasjoner

10 Mest negative korrelasjoner

Visste du det?

Korrelasjon er en statistisk måling som beskriver forholdet mellom to variabler. Den varierer fra -1 til 1, hvor -1 indikerer en perfekt negativ korrelasjon (hvor en variabel øker, går den andre ned), 1 indikerer en perfekt positiv korrelasjon (hvor en variabel øker, går den andre også opp), og 0 indikerer ingen korrelasjon (det er ingen forhold mellom variablene).

Korrelasjon kan brukes til å analysere forholdet mellom to variabler, ikke bare aksjer. Det er vanligvis brukt innen områder som finans, økonomi, psykologi, og mer.

Healios K.K. Korrelasjon - Valuta/Råvare

0.31
( neutral )

0.37
( neutral )

-0.28
( neutral )

0.12
( neutral )

0.06
( neutral )

Healios K.K. Økonomi

Annual	2023
Omsetning:	¥121.00M
Bruttogevinst:	¥-265.00M (-219.01 %)
EPS:	¥-56.22

FY	2023
Omsetning:	¥121.00M
Bruttogevinst:	¥-265.00M (-219.01 %)
EPS:	¥-56.22

FY	2022
Omsetning:	¥90.00M
Bruttogevinst:	¥90.00M (100.00 %)
EPS:	¥-90.69

FY	2021
Omsetning:	¥41.00M
Bruttogevinst:	¥41.00M (100.00 %)
EPS:	¥-46.81

Financial Reports:

No articles found.

Healios K.K.

Healios K.K. engages in the research and development, manufacture, and sale of cell therapy and regenerative medicine products in Japan, Europe, and the United States. The company is also developing cellular and tissue-based products comprising HLCR011 and HLCR012 that are iPSC regenerative medicines for the treatment of age-related macular degeneration; HLCL041, an iPSC regenerative medicine for the treatment of metabolic liver disease; and HLCM051, a regenerative medicine for treatment of ischemic stroke and acute respiratory distress syndrome, as well as HLCN061 for treating solid tumors. Healios K.K. has a joint research agreement with the Hyogo Medical University on cancer immunotherapies for mesothelioma using eNK cells. The company was formerly known as Retina Institute Japan, K.K. and changed its name to Healios K.K. in September 2013. Healios K.K. was incorporated in 2011 and is headquartered in Tokyo, Japan.